Table 2.

Current and emerging approaches to enhance allogeneic HCT for nonmalignant disease

	Current approaches	Emerging approaches
Conditioning regimens	Use of traditional agents in combinations that limit toxicities	Antibody-based conditioning (anti-CD117, anti-CD45)
Graft sources	Unmanipulated BM, PBSC, or UCB	Ex vivo UCB expansion (nicotinamide)
GVHD prophylaxis	CNI-based prophylactic regimens Addition of ATG PTCy-based prophylactic regimens Traditional T-cell depletion	Wider adoption of PTCy-based regimens Novel targeted agents (CD24, CD26, α4β7 integrin, JAK1 or JAK 1/2, T-cell costimulation) Novel depletion approaches (CD3+/CD19+, TCRαβ+, CD45RA+) Infusion of ex vivo expanded or highly purified regulatory T-cells after CD34+ selected HCT

JAK, Janus kinase.